[go: up one dir, main page]

AR027399A1 - Compuestos heterociclicos utiles como inhibidores de la fosfodiesterasa iv, composiciones formuladas con dichos compuestos y uso de dichos compuestos parapreparar dichas composiciones - Google Patents

Compuestos heterociclicos utiles como inhibidores de la fosfodiesterasa iv, composiciones formuladas con dichos compuestos y uso de dichos compuestos parapreparar dichas composiciones

Info

Publication number
AR027399A1
AR027399A1 ARP010100598A ARP010100598A AR027399A1 AR 027399 A1 AR027399 A1 AR 027399A1 AR P010100598 A ARP010100598 A AR P010100598A AR P010100598 A ARP010100598 A AR P010100598A AR 027399 A1 AR027399 A1 AR 027399A1
Authority
AR
Argentina
Prior art keywords
compounds
compositions
phosphodesterase
preparate
inhibitors
Prior art date
Application number
ARP010100598A
Other languages
English (en)
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of AR027399A1 publication Critical patent/AR027399A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Se trata de compuestos inhibidores de la fosfodiestersa, tienen utilidad terapéutica y tienen la formula general (1) donde R1 es C3-6 cicloalquilo o C1-3alquilo opcionalmente sustituido con uno o más átomos de fluor; R2 es C1-alquilo, C3-6 cicloalqui lo, CF3, CH2CF3, C2F5 o NR4R5; R3 es un grupo pirazol,imidazol o isoxazol de formula parcial (A), (B) o (C); NR4R5 es un anillo heterocíclico que contiene nitrogeno; R6 es C1-3 alquilo; y R7 y R8, que son igualeso diferentes, son cada uno H, C1-3 alq uilo, halogeno, CF3 o CN, siempre que ambos no sean H; o sales farmacéuticamente aceptables de los mismos.
ARP010100598A 2000-02-11 2001-02-09 Compuestos heterociclicos utiles como inhibidores de la fosfodiesterasa iv, composiciones formuladas con dichos compuestos y uso de dichos compuestos parapreparar dichas composiciones AR027399A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0003254.0A GB0003254D0 (en) 2000-02-11 2000-02-11 Heterocyclic compounds and their therapeutic use

Publications (1)

Publication Number Publication Date
AR027399A1 true AR027399A1 (es) 2003-03-26

Family

ID=9885477

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100598A AR027399A1 (es) 2000-02-11 2001-02-09 Compuestos heterociclicos utiles como inhibidores de la fosfodiesterasa iv, composiciones formuladas con dichos compuestos y uso de dichos compuestos parapreparar dichas composiciones

Country Status (10)

Country Link
US (1) US6313116B1 (es)
EP (1) EP1263757B1 (es)
JP (1) JP2003522772A (es)
AR (1) AR027399A1 (es)
AT (1) ATE300537T1 (es)
AU (1) AU2001233837A1 (es)
DE (1) DE60112254T2 (es)
GB (1) GB0003254D0 (es)
PE (1) PE20011290A1 (es)
WO (1) WO2001058897A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005116009A1 (en) * 2004-05-18 2005-12-08 Schering Corporation Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors
TWI306401B (en) 2004-08-13 2009-02-21 Nat Health Research Institutes Benzothiazolium compounds
US7643818B2 (en) * 2004-11-22 2010-01-05 Seven Networks, Inc. E-mail messaging to/from a mobile terminal
SE0403117D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab New compounds 1
WO2006109817A1 (ja) * 2005-04-06 2006-10-19 Banyu Pharmaceutical Co., Ltd. １，４－置換ピペラジン誘導体
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007229492B2 (en) 2006-03-28 2011-11-03 High Point Pharmaceuticals, Llc Benzothiazoles having histamine H3 receptor activity
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009002496A (es) * 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100111800A1 (en) * 2008-11-03 2010-05-06 Westinghouse Electric Company Llc PRODUCTION OF NUCLEAR GRADE ENRICHED GADOLINIUM AND ERBIUM USING VOLATILE Gd OR Er SPECIES USING AN AERODYNAMIC PROCESS
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CN110367188A (zh) * 2019-04-04 2019-10-25 上海大学 心肌层转染慢病毒的小鼠模型的构建方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268037A1 (en) * 1996-11-15 1998-05-28 Darwin Discovery Limited Bicyclic aryl carboxamides and their therapeutic use
NZ503491A (en) * 1997-11-10 2002-08-28 Bristol Myers Squibb Co 2-substituted amino-1,3-benzothiazole derivatives useful as protein tyrosine kinase inhibitors

Also Published As

Publication number Publication date
GB0003254D0 (en) 2000-04-05
JP2003522772A (ja) 2003-07-29
DE60112254T2 (de) 2006-05-24
US6313116B1 (en) 2001-11-06
DE60112254D1 (de) 2005-09-01
AU2001233837A1 (en) 2001-08-20
EP1263757B1 (en) 2005-07-27
WO2001058897A1 (en) 2001-08-16
PE20011290A1 (es) 2001-12-20
EP1263757A1 (en) 2002-12-11
ATE300537T1 (de) 2005-08-15

Similar Documents

Publication Publication Date Title
AR027399A1 (es) Compuestos heterociclicos utiles como inhibidores de la fosfodiesterasa iv, composiciones formuladas con dichos compuestos y uso de dichos compuestos parapreparar dichas composiciones
UY26727A1 (es) Derivados de tropano útiles en terapia
AR016762A1 (es) Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo
AR008750A1 (es) Formas de dosis farmaceuticas orales que comprende un inhibidor de bombeo protonico y un agente procinetico, proceso para su fabricacion y uso de dichasformas para la fabricacion de medicamentos
TR200002505T2 (tr) Siklik amino bileşikleri
WO2003106428A8 (fr) Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine
DE69618231D1 (de) TETRAHYDROIMIDAZOPYRIDOINDOLDIONE ALS cGMP SPEZIFISCHE PDE HEMMER
AR027518A1 (es) Inhibidores de girasas y usos de los mismos
AR024158A1 (es) Compuestos antibacterianos
AR049578A1 (es) Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
ATE300543T1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
AR063294A1 (es) Composiciones de carbamatos de fenilalquilo
AR033427A1 (es) Uso de compuestos carbamatos en el tratamiento del dolor
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
DK0759027T3 (da) Bicykliske amidinderivater som inhibitorer af nitrogenoxidsynthetase
PE20020906A1 (es) Inhibidores de peptido-deformilasa
AR054551A1 (es) Metodos para la neuroproteccion
ES2095662T3 (es) Derivados de imidazol con actividad antagonista de la angiotensina ii.
CO4810374A1 (es) Nueva utilizacion de compuestos para actividad anti- pruritica
ATE282037T1 (de) Benzoxazolderivate als tnf und pde iv inhibitoren
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
AR052885A1 (es) Metodos para el control del intervalo qt
DE60110124D1 (de) Kondensierte pyrazindionderivate als pde inhibitoren
FI945582A0 (fi) Substituoidut (aryylialkyyliaminobentsyyli) aminopropioniamidijohdannaiset, niiden valmistus ja käyttö anti-epileptisinä, neuroprotektiivisina ja antidepressiivisina aineina
AR035601A1 (es) Procesos de preparacion de inhibidores del intercambiador de sodio-hidrogeno de tipo 1, inhibidores, sales de dichos compuestos, composiciones farmaceuticas y uso de los mismos en la preparación de medicamentos

Legal Events

Date Code Title Description
FB Suspension of granting procedure